HoFH, the International Clinical Collaborators Registry
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- University of Pennsylvania
- Study ID
- NCT04815005
- Status
- Recruiting
Conditions
- Homozygous Familial Hypercholesterolemia
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence. — OTHERDifferences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
Study Details
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.
Key Dates
- Start date
- Jan 24, 2017
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: HoFHPatients diagnosed with HoFH by their physicians, either based on clinical or genetic criteria.
Primary Outcome Measure
Number of participants entered into the database [ Time Frame: Through study completion, an average of 8 years ]
Central Contacts
- Marina Cuchel, MD, PhD2156627188
- Lauren Vincent, MRA2156155448
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Marina Cuchel, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Philadelphia, PA
Related Studies
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)PHASE3 · Recruiting · Arrowhead Pharmaceuticals · Park Ridge, Illinois
- The Rogosin Institute Homozygous Familial Hypercholesterolemia RepositoryRecruiting · The Rogosin Institute · New York, New York